Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of KBA1412 alone or with pembrolizumab in advanced solid tumors
NL-OMON53468Phase 1Recruiting
- Sponsor
- Kling Biotherapeutics
- Start
- Sep 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of kba-1412 and pembrolizumab in Nonhematologic neoplasms, melanoma, ovarian cancer and 2 more (3 arms), sponsored by Kling Biotherapeutics. Started Sep 2022; status: recruiting.
02
Drugs
kba-1412pembrolizumab
03
Conditions
Nonhematologic neoplasmsmelanomaovarian cancergastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON53468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53468.